Navigation Links
Taiho Pharmaceutical unveils data on 8 novel anticancer compounds
Date:11/6/2012

DUBLIN, November 6, 2012 Taiho Pharmaceutical Co., Ltd. (HQ: Tokyo, President: Masayuki Kobayashi), the developer of the first orally available fluorouracil (FU) Chemotherapeutic treatment (TS-1/S-1), is presenting early stage data for eight novel oncology compounds, including potential first-in-class therapies. The data being presented during the 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics from November 6 9, 2012 in Dublin, Ireland underscore Taiho's steadfast commitment to improving cornerstone anti-metabolic cancer agents and developing novel molecular targeted therapies that can be used alone or in combination worldwide.

"The data being presented demonstrate Taiho's ability to develop novel molecular targeted agents as well as next generation cytotoxic therapies, and underscore our continued commitment to developing investigational anticancer drugs that have the potential to improve treatment options available to cancer patients," said Masayuki Kobayashi, Taiho Pharmaceutical's president. "Our strategy surrounding innovative research and clinical development reinforces Taiho's pursuit of becoming a top-ten oncology company in the next decade."

Rapid Advancement

Taiho established a foundation of innovative product development 50 years ago, and the Company is committed to achieving efficiencies to effectively yield rapid results. This commitment is best demonstrated by the recent movement of the TAS-102 antitumor agent through preclinical and clinical development. Preclinical results being presented at the EORTC-NCI-AACR Symposium show that TAS-102 exhibited marked tumor growth delay after drug treatment due to FTD incorporation into DNA when evaluated using a well-recognized animal model for breast cancer, and a survival benefit in a colon cancer model.

A Phase II study of TAS-102, conducted in Japan, demonstrated an improvement in overall survival of patients with metastatic
'/>"/>

Contact: Kerry Sinclair
kerry.sinclair@gcihealth.com
310-967-2952
GCI Health
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Medical care presents update on pharmaceutical health services research
2. Scientists use sound waves to levitate liquids, improve pharmaceuticals
3. Pharmica Consulting to Hold HIT Conference for the Pharmaceutical Industry
4. Is it constitutional for states to regulate pharmaceutical gifts and meals to doctors?
5. 5 more pharmaceutical companies join NIH initiative to speed therapeutic discovery
6. Nobel laureate to keynote international pharmaceutical conference at URI
7. MSU invention could help pharmaceutical industry save money
8. Global, common approach to pharmaceutical supply chain integrity the focus of workshop
9. 'EMT Exam Ace' Unveils Free Sample EMT Practice Quizzes
10. DRE Medical Equipment Unveils FX-300+ Surgical Headlight and Light Source
11. CustomerCentric Selling® Unveils New Client Testimonial Videos to Showcase Significant Sales Success
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... pain relief targets that could be used to ... King,s College London made the discovery when researching ... of the body. , Dr Marzia Malcangio said: ... pain generation and our findings could help chemotherapy ... One potential side effect of some chemotherapy drugs ...
(Date:4/17/2014)... the University of California, San Diego School of Medicine ... have suffered a recent major loss are more likely ... , The study is published in this month,s issue ... , Because compassionate behaviors are associated with better health ... insights into ways to improve the outcomes of individuals ...
(Date:4/17/2014)... created a new technology for modifying human cells ... body and selectively target cancer and other sites ... monitor and modify human physiology is a promising ... technology enabled bioengineers to build such devices that ... a customized fashion. , "The project addressed a ...
(Date:4/17/2014)... NY (April 16, 2014) The cause of neuronal ... new study proposes that neurons may be mistaken for ... system, similar to the way autoimmune diseases like type ... body,s cells. The study was published April 16, 2014, ... new, and likely controversial, idea in Parkinson,s disease; but ...
(Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit organization ... published a comprehensive review today examining the current state ... The review calls for improved global surveillance strategies to ... recent outbreak of Ebola in West Africa that has ... of Guinea and Liberia. According to the World ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2Health News:Is Parkinson's an autoimmune disease? 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3
... effects, is serious enough to be considered a health risk. ... or fewer hours were more likelier to have a heart ... too much sleep isn't good, either, as researchers found that ... also increased their heart disease risk. ,The study, conducted ...
... rate for potential medical problems, according to earlier studies, is ... for babies in hospitals are even higher. However, a new ... Agency for Healthcare Research and Quality (AHRQ) may help prevent ... is aimed at pediatricians and parents, and includes a fact ...
... the United States have found that the practice of ... past 14 years. However, they suggested that patients with ... Pylori(H.Pylori) infection rather than receiving treatment for the infection ... appropriate option// than empiric treatment in patients with peptic ...
... wasting condition which is a serious problem in people with ... bowel, liver, lungs and heart. A recent study has found ... in fruit flies, where it is involved in muscle development, ... ,Researchers have been studying the function of the twist ...
... has identified independent factors that are associated with ... the study, information was gathered from the 1999 ... evaluate common factors in 1,810 diabetic Americans.// ... were found to have more primary care and ...
... The myth that eating nuts makes one fat has ... mono and polyunsaturated fats are good while simple carbohydrates ... low-density lipoprotein cholesterol, the good kind. Monounsaturated fat does ... in heart disease. ,Preliminary evidence shows that even ...
Cached Medicine News:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
(Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... 10 Eli Lilly and Company (NYSE: LLY ... the Second Circuit has agreed with Lilly,s position that a ... payor suit, in which unions and insurers who act as ... court also agreed with Lilly that plaintiffs, overpricing claims should ...
... (NYSE Amex: PTN ) announced that it will ... Conference / 12th Annual Healthcare Conference on Tuesday, September 14, ... September 12-15 at the New York Palace Hotel in New ... Chief Executive Officer of Palatin Technologies, will provide an update ...
Cached Medicine Technology:U.S. Court of Appeals Reverses Third-Party Payor Class Certification Suit Against Lilly 2
Designed to meet the demands of today's laboratories for RO water....
... L/day of Type III Laboratory-grade Water, RiOs ... up to 8000 L/day of Type III ... Complete Purification and Control Unit, RiOs systems ... providing total control of all parameters within ...
... RiOs systems produce Type III, laboratory-grade ... Systems are fed directly with potable tap ... a compact system design that is easy ... over the water produced at a low ...
... Model U410 is an upright freezer ... our Innova line, but using conventional ... a cost-effective alternative. Similar in size ... 240 2" boxes. Includes five compartments ...
Medicine Products: